FGFR3 Amplification

CI-VAR-00000244Explore in graph →CIViC 2906

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Ewing Sarcoma1
FGFR3 Amplification	Pazopanib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7835 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that responde… (full text at CIViC) PMID 28377484 · Subbiah et al., 2017 · Open in CIViC	civic
Malignant Breast Neoplasm1
FGFR3 Amplification	Pazopanib	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7955 Patients with breast cancer had their tumor samples analyzed by Foundation Medicine in order to determine an appropriate clinical trial with targeted therapy or retrospectively to correlate with respo… (full text at CIViC) PMID 27489863 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Gastric Neoplasm1
FGFR3 Amplification	Ponatinib	Predictive	D	Supports Sensitivity Response	3	rejected	EID8061 In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC	civic

Malignant Neoplasm1
FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification	Erdafitinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12024 In this phase II trial, 35 patients harbouring tumours with FGFR1-4 amplifications were treated with FGFR1-4 inhibitor, erdafitinib. 33 of the 35 patients were eligible and treated, while biopsies wer… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC	civic